Oncology Exchange
Frequently Asked Questions Regarding the Management of Multiple Myeloma in the Community Setting
Breast Cancer - Emerging Agents in Her2-postitive Breast Cancer
Emerging Strategies for the Management of Recurrent Ovarian Cancer
Non-Hodgkin's Lymphoma - Emerging Agents in Relapse/Refactory Non-Hodgkin's Lymphoma
Gastrointestinal Stromal Tumors - Emerging Multidisciplinary Approaches for the Management of Gastrointestinal Stromal Tumors
Challenges in Treating Renal Cell Carcinoma in the Community
Current Treatment Strategies for Chronic Myelogenous Leukemia
Personalizing Treatment for NSCLC An Oncology Exchange Program
Evidence-based Management of Metastatic Colorectal Cancer
Evolving Treatment Strategies for Mantle Cell Lymphoma in Elderly Patients
Emerging Strategies in Newly Diagnosed and Relapsed/Refractory Hodgkin Lymphoma
Rockpointe.com The confluence of medical science and clinical need

Oncology Exchange:
Evidence-based Management of Metastatic Colorectal Cancer

A series of Live Grand Rounds Programs, an ASCO State Affiliate Meeting, and an on-demand CME-certified Webcourse

Welcome to "Oncology Exchange: Evidence-based Management of Metastatic Colorectal Cancer." This CME-certified initiative is intended for community-based medical oncologists, surgical oncologists, radiation oncologists, and other health care professionals involved in the care of patients with metastatic colorectal cancer (mCRC). A series of live CME-certified activities will be presented at selected hospitals and an ASCO State/Regional Affiliate Meeting throughout the US during 2014, and an online CME-certified webcourse will be available in May of 2014.

Program Description:

The treatment armamentarium for mCRC has expanded significantly with the recent approval of several novel therapies. These advances have led to a widening of the gap between evidence-based practice guidelines and the practice patterns of community oncologists and other health care professionals who treat patients with mCRC.

Evidence-based Management of Metastatic Colorectal Cancer is designed to educate oncologists on the recent practice-changing data from ongoing clinical studies and to provide guidance on integrating evidence-based novel therapies into their clinical practices.

Accreditation Statements:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statements:

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For information about the accreditation of this program, please email contact@pcme-rockpointe.com.

Calendars for Live Activities

Back to Top

Visiting Professor Series

Chapter Meetings


Related Online Offerings

Back to Top

A companion webcourse for this program can be found at: http://www.oncexchange.com/CRCCME.

Additional Oncology CME/CE-certified online activities can be found at: http://www.medscape.org/sites/advances/oncologyexchange.

Live Program Materials for Speakers and Administrators

Back to Top

I. Administrator Material

II. Speaker Material

Audio Orientation

Thank you for joining us as an expert speaker for the 2014 Grand Rounds Series, "Oncology Exchange: Evidence-based Management of Metastatic Colorectal Cancer."

This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:

  • Emerging evidence supporting the role of prognostic and predictive markers for personalized treatment planning in mCRC
  • Updated clinical guidelines and newly approved agents for mCRC treatment planning
  • Evidence-based data for patients with mCRC beyond progression

This program has been recorded by the steering committee for use as an enduring webcourse. Speakers may use this webcourse as a speaker orientation.

Click here to view the webcourse. (Coming soon)

Download Transcript (PDF)

Audio download of Speaker Orientation (ComingSoon)

Audio Download

CME-certified Program Slides

This version of the program slides has been CME/CE-certified and these slides are to be used for this activity. Download (PowerPoint) Coming Soon

Steering Committee and Speaker Biographies

Back to Top

AXEL GROTHEY, MDAXEL GROTHEY, MD
Professor of Oncology
Mayo Clinic College of Medicine
Rochester, MN


Axel Grothey, MD is a consultant in the Division of Medical Oncology, Department of Oncology, at the Mayo Clinic College of Medicine in Rochester, MN. He holds the academic rank of Professor of Oncology and has teaching/examining privileges in clinical and translational science at the Mayo Graduate School. He is also a member of the Mayo Clinic's Cancer Center.

Dr. Grothey received his medical degree at Ruhr-Universitat Bochum in Germany, and completed residencies at West-German Tumorcenter and the Institute of Pathology at the University of Essen, as well as a residency and fellowship at the University of Bochum. He also completed a research fellowship at the MD Anderson Cancer Center at the University of Texas. He joined the Mayo Clinic as a consultant in 2005.

Dr. Grothey's clinical interests focus on gastrointestinal cancers, in particular, colorectal cancer, anti-angiogenesis, signal transduction inhibitors, and clinical trial design and statistics. As a consultant and investigator, his research has been funded by the National Cancer Institute (NCI) and the National Institutes of Health (NIH), among other organizations. He currently chairs the NCI Colon Cancer Task Force, and serves as Vice-chair of the Gastrointestinal Cancer Committee of the Alliance for Clinical Trials in Oncology, an NCI-funded cooperative group. He is also chair of the Academic and Community Cancer Research United (ACCRU) international research network.

Dr. Grothey serves in journal review and editorial capacities for numerous medical journals and is an Editor for Clinical Colorectal Cancer, Emerging Cancer Therapeutics, OncologySTAT, and Therapeutic Advances in Medical Oncology. He is a 5-time recipient of the Teacher of the Year recognition at the Mayo Clinic and has given numerous international, national, and regional presentations, as well as many invited and visiting professor presentations. He has co-authored more than 250 articles, books, book chapters, editorials, abstracts, and letters.


JOHN L. MARSHALL, MDJOHN L. MARSHALL, MD
Chief, Hematology and Oncology
Professor of Medicine and Oncology
Director, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers
Lombardi Comprehensive Cancer Center
Georgetown University
Washington DC


John L. Marshall, MD received his training at Duke University, the University of Louisville, and Georgetown University. Dr. Marshall is an internationally recognized expert in new drug development for gastrointestinal (GI) cancers, with expertise in phase I, II, and III trial design, and has served as Principal Investigator for more than 100 clinical trials.

While he has an interest in many areas of cancer research, Dr. Marshall's primary focus has been on the development of vaccines to treat cancer. He has become an outspoken advocate for GI-cancer patients and of the importance of clinical-research participation. Most recently, he established the Otto J Ruesch Center for the Cure of Gastrointestinal Cancers, an organization solely focused on improving the lives of GI cancer patients through innovative research, personalized medicine, and focused advocacy.

Back to Top
Jointly provided by:    and  
Supported by an educational grant from:
©2014 PCME